Toronto - A group of Canadian physicians who use Artecoll, an injectable currently awaiting FDA approval, is calling for the development of formal clinical guidelines and further research to help avoid adverse patient reactions.
Treating Body Dysmorphic Disorder in Cosmetic Patients
The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques
Study Finds Successful Switching Strategy for Patients with Psoriasis After Suboptimal Response
The Cutaneous Connection- Episode 35: QRPs and the Dermatology Practice
Establishing a Culture of Respect: Responding to Patient-Initiated Harassment
Advancements in Understanding the Skin's Microbiomes
2 Clarke Drive Cranbury, NJ 08512